Literature DB >> 1350485

Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure.

I W Franz1, B Agrawal, D Wiewel, R Ketelhut.   

Abstract

The present study was conducted to assess the efficacy and safety of carvedilol 50 mg as compared to metoprolol 200 mg at rest and during and after a standardized bicycle ergometric exercise test. Carvedilol is a novel non-selective beta-blocker without intrinsic sympathomimetic activity possessing vasodilatory properties primarily due to an alpha 1-antagonism in the same dose range. Both drugs were effective in reducing systolic and diastolic blood pressure at rest and during and after exercise. The reduction of diastolic blood pressure was much stronger under carvedilol treatment than under metoprolol treatment at all measurement points. Carvedilol was even effective in the treatment of patients whose blood pressure was unsatisfactorily controlled by metoprolol. This shows the importance of the vasodilation component of carvedilol. No serious adverse events were observed. Carvedilol therefore promises very well as a powerful and safe drug for the treatment of essential arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350485     DOI: 10.1007/bf00207612

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  24 in total

1.  Effects of carvedilol in patients with impaired left ventricular function due to ischaemic heart disease.

Authors:  A Lahiri; E A Rodrigues; P DasGupta; D Jain; R van der Does; E B Raftery
Journal:  Z Kardiol       Date:  1989

2.  Antianginal efficacy of carvedilol, a beta-blocking drug with vasodilating activity.

Authors:  E A Rodrigues; A Lahiri; L O Hughes; R S Kohli; J R Whittington; E B Raftery
Journal:  Am J Cardiol       Date:  1986-11-01       Impact factor: 2.778

3.  Assessment of blood pressure response during ergometric work in normotensive and hypertensive patients.

Authors:  I W Franz
Journal:  Acta Med Scand Suppl       Date:  1982

4.  Excessive plasma dopamine increase at rest and during exercise after long-term beta-adrenoreceptor blockade in hypertensive patients.

Authors:  I W Franz; F W Lohmann; G Koch
Journal:  Br Heart J       Date:  1980-07

5.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

6.  [Regression of myocardial hypertrophy in hypertensives on chronic beta-receptor block].

Authors:  I W Franz; D Wiewel; M Behr; R Ketelhut
Journal:  Dtsch Med Wochenschr       Date:  1986-04-04       Impact factor: 0.628

7.  Assessment of left-ventricular mass and its response to antihypertensive treatment.

Authors:  D B Rowlands; D R Glover; M A Ireland; R A McLeay; T J Stallard; R D Watson; W A Littler
Journal:  Lancet       Date:  1982-02-27       Impact factor: 79.321

8.  Cuff and ambulatory blood pressure in subjects with essential hypertension.

Authors:  J S Floras; J V Jones; M O Hassan; B Osikowska; P S Sever; P Sleight
Journal:  Lancet       Date:  1981-07-18       Impact factor: 79.321

9.  [The effect of beta-receptor antagonists and diuretics and their combination on blood pressure and pressure-rate product during ergometric work in hypertensive patients (author's transl)].

Authors:  I W Franz
Journal:  Z Kardiol       Date:  1982-01

10.  Antianginal efficacy of carvedilol, a new beta-blocker with vasodilating action.

Authors:  S M Jamal; S B Freedman; A Thomson; G Carter; P J Harris; D T Kelly
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

View more
  2 in total

Review 1.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 2.  Antihypertensive profile of carvedilol.

Authors:  W Meyer-Sabellek; B Agrawal
Journal:  Clin Investig       Date:  1992
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.